logo
Twitter
Discord
Email
logo
Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated

NASDAQ•VRTX
CEO: Dr. Jeffrey Marc Leiden M.D., Ph.D.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 1991-07-24
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Contact Information
50 Northern Avenue, Boston, MA, 02210, United States
617-341-6100
www.vrtx.com
Market Cap
$113.16B
P/E (TTM)
30.7
38.2
Dividend Yield
--
52W High
$519.68
52W Low
$362.50
52W Range
50%
Rank29Top 17.8%
5.2
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Average • 5.2 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025

Financial Dashboard

Q3 2025 Data

Revenue

$3.08B+10.98%
4-Quarter Trend

EPS

$4.24+4.69%
4-Quarter Trend

FCF

$1.14B-12.48%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Nine Month Revenue Growth Total revenues reached $8.81B USD for nine months ended September 30, 2025, marking an 9% increase versus prior year.
Strong Net Income Performance Net income was $2.76B USD for nine months 2025, a significant turnaround from the $(1.45B) loss reported in 2024.
Cash and Securities Increase Total cash, cash equivalents, and marketable securities grew 7% to $12.01B USD as of September 30, 2025.
CF Product Revenue Strength TRIKAFTA/KAFTRIO product revenues totaled $7.74B USD for nine months 2025, showing 3% growth over 2024 period.

Risk Factors

Intangible Asset Impairment Recorded $379.0M USD intangible asset impairment charge in Q1 2025 following VX-264 clinical trial discontinuation decision.
ALYFTREK Royalty Dispute Royalty Pharma initiated arbitration alleging 8% royalty burden on ALYFTREK sales, contrary to company's 4% position.
Increased Operating Expenses Total costs and expenses rose 14% to $5.84B USD for nine months 2025, driven by R&D and SG&A increases.
Contingent Consideration Liability Fair value of contingent consideration liability was $78.1M USD as of September 30, 2025, reflecting potential future payments.

Outlook

Povetacicept BLA Submission Expect submission of first module for IgAN Biologics License Application before year-end 2025 for accelerated approval.
JOURNAVX Commercial Expansion JOURNAVX achieved access to over 170 million U.S. covered lives, expecting continued expansion through 2026.
Remaining Share Repurchase $3.5B USD authorization remains available under the 2025 Share Repurchase Program approved in May 2025.
Analyzing New Tax Law Assessing impact of recently enacted U.S. H.R.1 legislation on future effective tax rates, liabilities, and cash taxes.

Peer Comparison

Revenue (TTM)

CVS Health CorporationCVS
$394.08B
+6.8%
McKesson CorporationMCK
$387.09B
+17.2%
HCA Healthcare, Inc.HCA
$74.37B
+6.8%

Gross Margin (Latest Quarter)

argenx SEARGX
88.3%
-53.8pp
Vertex Pharmaceuticals IncorporatedVRTX
86.5%
+0.7pp
Regeneron Pharmaceuticals, Inc.REGN
86.1%
-0.7pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
MDT$124.11B26.09.8%31.9%
SNY$113.51B10.612.6%16.8%
VRTX$113.16B30.721.8%7.4%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
1.8%
Moderate Growth
4Q Net Income CAGR
5.9%
Profitability Improving
Cash Flow Stability
100%
Strong Cash Flow

Research & Insights

Next earnings:Feb 9, 2026
|
EPS:$5.05
|
Revenue:$3.18B
Reports
All Years
  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Nov 4, 2025|
    Revenue: $3.08B+11.0%
    |
    EPS: $4.24+4.7%
    Miss
  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Aug 5, 2025|
    Revenue: $2.96B+12.1%
    |
    EPS: $4.02-128.9%
    Miss
  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 6, 2025|
    Revenue: $2.77B+3.1%
    |
    EPS: $2.52-40.8%
    Miss
  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Feb 13, 2025|
    Revenue: $11.02B+11.7%
    |
    EPS: $-2.08-114.8%
    Miss
  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Nov 5, 2024|
    Revenue: $2.77B+11.6%
    |
    EPS: $4.05+1.0%
    Meet
  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 2, 2024|
    Revenue: $2.65B+6.1%
    |
    EPS: $-13.92-492.1%
    Miss
  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 7, 2024|
    Revenue: $2.69B+13.2%
    |
    EPS: $4.26+56.6%
    Beat
  • Form 10-K - FY 2023

    Period End: Dec 31, 2023|Filed: Feb 15, 2024|
    Revenue: $9.87B+10.5%
    |
    EPS: $14.05+8.3%
    Beat